SHANGHAI OPM BIOSCIENCES CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.87 CNY | +0.91% |
|
-4.48% | -45.86% |
| May. 09 | OPM Biosciences' Shareholder to Cut Stake | MT |
| Apr. 29 | Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 8,460 | 6,332 | 3,403 | - | - |
| Enterprise Value (EV) 1 | 8,460 | 6,332 | 3,403 | 3,403 | 3,403 |
| P/E ratio | 47.9 x | 117 x | 38.3 x | 22.9 x | 15.7 x |
| Yield | - | 0.42% | 1.1% | 2.48% | 4.89% |
| Capitalization / Revenue | - | 26 x | 9.78 x | 6.8 x | 4.96 x |
| EV / Revenue | - | 26 x | 9.78 x | 6.8 x | 4.96 x |
| EV / EBITDA | - | 66.2 x | 24 x | 15.2 x | 11.3 x |
| EV / FCF | - | -323 x | 81 x | -1,134 x | 51.6 x |
| FCF Yield | - | -0.31% | 1.23% | -0.09% | 1.94% |
| Price to Book | - | 2.93 x | 1.55 x | 1.49 x | 1.41 x |
| Nbr of stocks (in thousands) | 114,772 | 114,772 | 113,914 | - | - |
| Reference price 2 | 73.71 | 55.17 | 29.87 | 29.87 | 29.87 |
| Announcement Date | 2/23/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 243.1 | 347.8 | 500.4 | 685.6 |
| EBITDA 1 | - | 95.71 | 142 | 224 | 300 |
| EBIT 1 | - | 61.81 | 100.7 | 170.7 | 249.7 |
| Operating Margin | - | 25.42% | 28.94% | 34.11% | 36.42% |
| Earnings before Tax (EBT) 1 | - | 61.67 | 102.3 | 172 | 251 |
| Net income 1 | 105.4 | 54.04 | 89.4 | 149.9 | 218.7 |
| Net margin | - | 22.23% | 25.7% | 29.97% | 31.91% |
| EPS 2 | 1.540 | 0.4700 | 0.7800 | 1.307 | 1.907 |
| Free Cash Flow 1 | - | -19.59 | 42 | -3 | 66 |
| FCF margin | - | -8.06% | 12.07% | -0.6% | 9.63% |
| FCF Conversion (EBITDA) | - | - | 29.58% | - | 22% |
| FCF Conversion (Net income) | - | - | 46.98% | - | 30.17% |
| Dividend per Share 2 | - | 0.2300 | 0.3300 | 0.7400 | 1.460 |
| Announcement Date | 2/23/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -19.6 | 42 | -3 | 66 |
| ROE (net income / shareholders' equity) | - | 2.48% | 4.17% | 6.43% | 9.03% |
| ROA (Net income/ Total Assets) | - | - | 4.3% | 6.2% | 7.7% |
| Assets 1 | - | - | 2,079 | 2,418 | 2,841 |
| Book Value Per Share 2 | - | 18.80 | 19.20 | 20.10 | 21.20 |
| Cash Flow per Share 2 | - | 0.5000 | 1.110 | 1.200 | 2.080 |
| Capex 1 | - | 77.5 | 81 | 81 | 77 |
| Capex / Sales | - | 31.9% | 23.29% | 16.19% | 11.23% |
| Announcement Date | 2/23/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
29.87
CNY
Average target price
53.41
CNY
Spread / Average Target
+78.81%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -45.86% | 468M | |
| +3.11% | 97.7B | |
| +5.66% | 41.43B | |
| -12.80% | 32.85B | |
| +80.99% | 29.33B | |
| -15.53% | 15.47B | |
| -8.70% | 12.89B | |
| -12.22% | 11.51B | |
| +183.25% | 10.74B | |
| -55.41% | 8.97B |
- Stock Market
- Equities
- 688293 Stock
- Financials Shanghai OPM Biosciences Co., Ltd.
